More than one-half of adults with non-Hodgkin's B cell lymphomas present with low-grade follicular lymphomas. These tumor cells are found in dose association with follicular T lymphocytes and dendritic cells, suggesting that the surrounding ceils may play a role in the support of follicular tumors. Supernatants from activated human peripheral blood lymphocytes were found to promote the in vitro proliferation of follicular tumor cells. This effect was entirely due to interleukin 3 (IL-3), a factor generally thought to cause the growth and differentiation of immature hematopoietic cells. II.-3 receptors were detected on fresh isolates of all primary follicular cell tumors examined. These findings suggest that follicular cell tumors may be dependent in vivo on II.-3 and that therapies directed against I1.-3, its receptor, or the T cells that produce it may be effective treatment for follicular lymphoma.
F
hollicular lymphoma, one of the most common hematologic malignancies in humans, is usually an indolent although ultimately fatal disease in which the tumor cells grow in close proximity to T cells and follicular dendritic cells. The median survival for all patients with follicular lymphoma is >6 yr (1) . For the majority of patients with follicular lymphoma, transformation to a diffuse large cell lymphoma signals the onset of a much more aggressive form of the disease in which the tumor cells appear no longer to require T cells or follicular dendritic cells. In these patients, median survival drops to <3 yr (1) . Unfortunately, the biology of follicular lymphoma and the etiology of transformation from follicular lymphoma to the more aggressive large cell lymphoma have been difficult to study because of the low success rate in deriving cell lines in vitro. In this report, we show that the in vitro growth of some follicular lymphomas is dependent upon provision of IL-3.
Materials and Methods
Cytokines and Antibodies. Human rlL-1-6 were purchased from Amgen Biotogicals (Thousand Oaks, CA). Supematant from PHA-P-activated human lymphocytes was prepared as described (2, 3) . Neutralizing rabbit anti-Ib3s was obtained from R & D Systems, Inc. (Minneapolis, MN). Expression of IL-3Rs was detected by flow cytometry using reagents from R & D System, Inc. The BL antiidiotype was prepared as described (4 
Results
A cell line designated BLT was established by culturing previously frozen spleen cells isolated from a patient with follicular B cell lymphoma. The growth of this cell line was completely dependent upon provision of media from mitogenactivated peripheral blood cells (2, 3) (Fig. 1) . Exponential growth with a doubling time of '~4 d was detected 10 wk after the initiation of culture.
The original splenic tumor expresses an Ig determinant (idiotype) that is unique to that particular tumor. To establish the origin of the cultured cell line, cells were analyzed for expression of the tumor idiotype and Ig isotype on a FACS | (Becton Dickinson & Co., Mountain View, CA) (Fig. 2) . The majority of the cells in the BLT cell line expressed the tumor idiotype and were surface IgM + . However, a portion of the BLT cells were IgM + , idiotype-. This phenotype was stable over many months of culture. To test whether the BLT cell line was composed of a mixture of tumor and nontumor cells, on two occasions, cells were stained with antiidiotype and sorted on a FACS | The resulting population (>95% idiotype positive) was put back in culture. After 2 wk, the profile was nearly identical to that shown in Fig. 2 , with only "~75% of the cells staining with antiidiotype. Thus, the idiotype-negative population may be due to selective loss of the idiotype determinant during culture or to the outgrowth of a second idiotype-negative population. Further confirmation that the cell line was derived from the original tumor came from Southern analyses of the Ig rearrangements. Identically rearranged bands were detected in the original tumor and the BLT cell line, but not PBL, using probes specific for C~ and J, (not shown). Finally, the t(14;18) translocation typical of most follicular lymphomas was present in both the original tumor and the BLT cell line (not shown).
As described above, the BLT tumor line was established in media supplemented with supernatants from mitogenactivated PBL. Attempts to grow the cell line in the absence Figure 1 . Growth of the BLT follicular tumor cell lines requires supernatants from mitogen-activated peripheral blood cells. BLT cells (106/ml) were washed twice in PBS and cultured in three 2-ml wells in the absence (@) or presence (VI) of 10% supernatant from PHA-P-activated peripheral blood cells; Aliquots were removed daily and assessed for viability by trypan blue exclusion. Cultures were supplemented with fresh media every 3 d and split as necessary. of these supernatants were unsuccessful, indicating that growth of the BLT tumor line required factors produced by activated white blood cells. To determine which, if any, known molecules stimulated the growth of this follicular tumor cell line, BLT tumor cells were cultured in the presence of a panel of recombinant human cytokines, and [3H]thymidine incorporation was assessed (Fig. 3 A) . II-3 induced proliferation equivalent to that caused by PBL supernatants. In contrast, I1-1, -2, -4, -5, and -6 did not cause increased [3H]thymidine incorporation relative to the medium alone. Moreover, various combinations of Ibl-6 did not result in any alteration in the pattern of proliferation induced by each interleukin alone (not shown).
Supernatants from activated PBL contain many molecules other than I1"1-6 (4). To test whether the proliferation of the BLT line in response to activated PBL medium was solely in response to I1"3, neutralizing antibodies were added to the proliferation assays (Fig. 3 B) .
[3H]Thymidine incorporation was completely abrogated when anti-I1"3 antibodies were added to cultures supplemented with either activated PBL supernatant or riD3. These data demonstrate that the in vitro proliferation of the BLT follicular lymphoma cell line is dependent upon I1-3.
Although the BLT cell line is dearly derived from the primary follicular tumor, it remained possible that the stimulatory effect of I1-3 on cell proliferation was unique to that cultured cell line. Therefore, the effects ofrI1"3 and activated PBL supernatants on the in vitro proliferation of a panel of primary follicular lymphomas was examined. In all four cases tested, addition of activated PBL supernatants or rll~3 resulted in marked increases in [3H]thymidine incorporation relative to that induced by medium alone (Table 1) . To ensure that the proliferating cells were in fact tumorous, a case was selected for which a mAb specific for the tumor idiotype was available. Cells were obtained from excised spleen and cultured for 4-6 wk in medium supplemented with ri1-3 or with PHAactivated T cell supernatant (Fig. 4) . Cells cultured with I1-3 were 100% positive for staining with the antitumor idiotype antibody, whereas only T cells were detectable in parallel cultures grown for 4-6 wk in the presence of T cell supernatants containing I1"2. In our experience, the ability of supernatants from activated T cells to promote the growth of T cells or tumor cells can vary for each patient sample. ri1-3 did not have any effect on the proliferation of peripheral blood cells and normal splenocytes (Table 1) , or a variety of other primary B cell tumors, including diffuse large cell, Burkitt's, and chronic lymphocytic leukemias (not shown). Moreover, all samples of primary follicular lymphomas tested expressed high levels of I1"3Rs (Fig. 5) . The single case of large cell lymphoma that was examined was also positive for expression of IL-3Rs. In contrast, PBL and normal splenocytes were negative. Two-color FACS | analysis was used to show that in a sample of fresh follicular lymphoma, all cells that expressed I1-3tks coexpressed Ig (Fig. 6) . In contrast, a sample of primary Burkitt's lymphoma was surface Ig positive, but I1-3R negative (Fig. 6) . Expression of IL-3Rs on an extended panel of other types of primary tumors has not been examined. chromosomal breaks are focused at the 5' ends of J. regions of the Ig genes, suggesting that the translocation occurred during attempted heavy chain joining at the pre-B cell stage. Thus, it is tempting to speculate that follicular lymphomas have retained some specific characteristics of pre-B cells, such as the ability to respond to Ib3. Independent evidence supports the notion that T cells and T cell-derived factors may be involved in the maintenance or proliferation of follicular lymphoma tumors. Both CD4 + and CD8 + T cells are found in intimate association with follicular lymphoma cells in vivo (1) . It has been suggested that these T cells might facilitate the neoplastic process or mount an immune response against it (20) . Umetsu et al. (21) showed that an HLA-DR-specific CD4 § T cell clone induced proliferation of some follicular lymphoma cells in vitro. Hoelzer and colleagues (22) recently conducted a clinical trial using II.-3 in patients with normal hematopoiesis or bone marrow failure. 19 patients with advanced tumors were treated with IL-3 to assess its toxicity and biological effects. Of these, four patients had either follicular or large cell lymphomas. Two of these patients experienced significant progression of their disease while receiving II~3. The progression reversed spontaneously when IL-3 was discontinued. Collectively, these results indicate a prominent role for IL-3 in the biology of follicular tumors and imply that therapies directed against Ib3, its receptor, or the T cells that produce it may prove effective for these clinically important human tumors.
This work was supported in part by grants from the National Institutes of Health (CA-34233 and CA-49605). Alan M. Krensky is an Established Investigator of the American Heart Association. Sandra LunaFineman and Jeffrey E. Lee were supported by fellowships from the Training Program in Immunology (AI-07290).
